Pfizer Faces $2 Bil. Annual Goodwill Charges If Pooling Not Allowed In WL Bid
Executive Summary
Pfizer would incur goodwill expenses of approximately $2 bil. per year if it is required to use the purchase accounting method in its acquisition of Warner-Lambert, Pfizer said in a Nov. 15 court filing.
You may also be interested in...
Pfizer/Warner-Lambert Merger Talks Begin: AHP Vows To Press On
The merger negotiations between Warner-Lambert and Pfizer are likely to focus on the $1 bil. gap between Pfizer's offer and Warner's current stock market valuation.
Pfizer/Warner-Lambert Merger Talks Begin: AHP Vows To Press On
The merger negotiations between Warner-Lambert and Pfizer are likely to focus on the $1 bil. gap between Pfizer's offer and Warner's current stock market valuation.
Warner-Lambert Sales Productivity Would Be Focus Of Pfizer Integration
One focus of Pfizer's integration of Warner-Lambert would be on raising the productivity of the Parke-Davis sales organization to Pfizer's "best-in-class" level, Pfizer told a Nov. 16 meeting with securities analysts.